Video

Chapter 3: The Case for Extracellular Vesicles

Source: Advancing RNA

While EVPs (engineered viral-like particles) and extracellular vesicles (EVs) are still emerging technologies, panelists explain how developers can navigate regulatory expectations by adapting lessons learned from established viral vector products. Additionally, Aegle’s Gloria Matthews explains the benefits of working with EVs in comparison to LNPs.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Advancing RNA? Subscribe today.

Subscribe to Advancing RNA X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Advancing RNA

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)